Back

Comparative effectiveness of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors on cardiovascular outcomes: A comprehensive Bayesian network meta-analysis with intervention ranking

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (3) - Pharmacotherapy Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mohd Turzo Rahman

Flushing Hospital and Medical Center, Flushing (United States of America)

8 More presentations in this session

Presentation thumbnail
Discussant - Pharmacotherapy
Presentation thumbnail
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Ph2 Trial of Pacibekitug SC Quarterly or Monthly in Patients with Elevated hs-CRP and Chronic Kidney Disease: TRANQUILITY 90-Day Results
Professor D. Bhatt (New York City, US)
Presentation thumbnail
SGLT2 inhibitors on the prevention of contrast-induced acute kidney injury in patients with type 2 diabetes after coronary revascularization: a systematic review and meta-analysis
Doctor K. Dimitriadis (Athens, GR)
Abstract Video
Presentation thumbnail
Comparative effectiveness of angiotensin ii receptor blockers versus angiotensin-converting enzyme inhibitors in acute myocardial infarction
Doctor P. Sun (Tianjin, CN)
Abstract Video
Presentation thumbnail
GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis
Doctor M. Galli (Rome, IT)
Abstract Video

Access the full session

Session thumbnail
New perspectives in cardiology (3) - Pharmacotherapy

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Presentation
Baseline characteristics and clinical outcomes of patients with type 2 diabetes and cardiovascular disease treated with GLP-1 receptor agonists and SGLT2 inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources